Talimogene laherparepvec addition to pembrolizumab showed no significant clinical improvement in advanced melanoma
1. Talimogene laherparepvec plus pembrolizumab did not significantly increase progression-free survival or overall survival compared to placebo plus pembrolizumab in ...